SCHEMBL2453686

SCHEMBL2453686

[N]c1ncccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56899 0.67
SCHEMBL3801704 0.65
Hydrogen Sulfide SCHEMBL27838627 0.64
Hydrogen Sulfide SCHEMBL28130279 0.64
Hydrogen Sulfide SCHEMBL27509537 0.64
SCHEMBL2174053 0.64 ALDH1A1 (0.53)
Phosphine SCHEMBL27276080 0.62
Hydrogen Sulfide SCHEMBL29184282 0.62 ALDH1A1 (0.63)
Hydrochloric Acid SCHEMBL6534749 0.61 HDAC8 (0.44)
Iodide SCHEMBL28731796 0.61 HDAC8 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6316459-B1 O-benzyloxime ethers and crop protection agents containing these compounds BASF AG (DE) 2001-11-13 US claimed
US-5563168-A FUNGICIDES, INSECTICIDES BASF AKTIENGESELLSCHAFT (DE) 1996-10-08 US claimed
US-4359327-A HYDROGEN ELECTRODES, PARACYCLOPHANES AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (FR) 1982-11-16 US claimed
EP-3911640-B1 PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE ASTRAZENECA AB (SE) 2026-05-13 EP disclosed
US-12584120-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-03-24 US disclosed
US-20230407285-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. 2023-12-21 US disclosed
US-11603523-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2023-03-14 US disclosed
EP-3911640-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 EP disclosed
CN-113412258-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2021-09-17 CN disclosed
US-20200231584-A1 PCSK9 Inhibitors and Methods of Use Thereof ASTRAZENECA AB (SE) 2020-07-23 US disclosed
WO-2020150474-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO disclosed
US-8859543-B2 Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
EP-2545055-A1 IMIDAZO [1, 2 -A]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES Janssen Pharmaceutica, N.V. (BE) 2013-01-16 EP disclosed
US-20120329792-A1 IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES JANSSEN PHARMACEUTICA NV 2012-12-27 US disclosed
CN-102791713-A Imidazo [1,2-A ] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases JANSSEN PHARMACEUTICA NV 2012-11-21 CN disclosed
WO-2011110545-A1 IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES JANSSEN PHARMACEUTICA NV (BE) 2011-09-15 WO disclosed
EP-1694678-A2 PROCESS FOR PREPARING HEXAHYDROPYRIMIDO 1,2-A¨AZEPINE-2-CARBOXYLATES AND RELATED COMPOUNDS Merck & Co., Inc. (US) 2006-08-30 EP disclosed
WO-2005061501-A2 PROCESS FOR PREPARING HEXAHYDROPYRIMIDO[1,2-A]AZEPINE-2-CARBOXYLATES AND RELATED COMPOUNDS MERCK & CO., INC. (US) 2005-07-07 WO disclosed
US-5502187-A Pharmaceutically active bicyclic-heterocyclic amines THE UPJOHN COMPANY (US) 1996-03-26 US disclosed
US-4359327-A HYDROGEN ELECTRODES, PARACYCLOPHANES AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (FR) 1982-11-16 US disclosed